Systematic Review of the Efficacy and Safety of Shuxuening Injection in the Treatment of Unstable Angina

Fan, Genhao; Liu, Menglin; Liu, Jia; Chen, Xixi; Huang, Yühong

doi:10.1155/2022/6650763

Cited by 3 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14,15] SXN is a Chinese patent medicine processed from Ginkgo biloba extract, which has the effect of promoting blood circulation. [21,31] However, there is still a lack of strong evidence on the efficacy and safety of ERI combined with SXN in the treatment of acute cerebral infarction. The results of this study show that ERI combined with SXN can improve the curative effect, improve brain nerve function damage and hemorheology, and reduce the expression level of inflammatory factors.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…[14] Shuxuening injection (SXN) is a Chinese medicine extracted from Ginkgo biloba leaves. [20,21] Ginkgo biloba extract mainly includes ginkgolide and flavonoid glycosides. [21][22][23] Ginkgolide has a strong antioxidant effect, which can inhibit lipid peroxidation, scavenge oxygen free radicals, and effectively protect injured tissue.…”

Section: Introductionmentioning

confidence: 99%

“…[20,21] Ginkgo biloba extract mainly includes ginkgolide and flavonoid glycosides. [21][22][23] Ginkgolide has a strong antioxidant effect, which can inhibit lipid peroxidation, scavenge oxygen free radicals, and effectively protect injured tissue. [24,25] Studies have shown that this drug has a protective effect on nerve cells in the brain and can effectively relieve the clinical symptoms of patients with cerebral infarction.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis

Zhou

Shanfen

2023

Medicine

View full text Add to dashboard Cite

Background: Shuxuening injection (SXN) is a traditional Chinese medicine used in the treatment of cardiovascular diseases. Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined. Therefore, we evaluated the efficacy of ERI combined with SXN versus that of ERI alone in patients with acute cerebral infarction. Methods: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang electronic databases were searched up to July 2022. Randomized controlled trials comparing the outcomes of efficacy rate, neurologic impairment, inflammatory factors, and hemorheology were included. Odds ratio or standard mean difference (SMD) with corresponding 95% confidence intervals (CIs) were used to present the overall estimates. The quality of the included trials was evaluated by the Cochrane risk of bias tool. The study was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses. Results: Seventeen randomized controlled trials were included consisting of 1607 patients. Compared to ERI alone, treatment with ERI plus SXN had a greater effective rate than ER alone (odds ratio = 3.94; 95% CI: 2.85, 5.44; I2 = 0%, P < .00001), a lower National Institute of Health Stroke Scale (SMD= −1.39; 95% CI: −1.73, −1.05; I2 = 71%, P < .00001), lower neural function defect score (SMD= −0.75; 95% CI: −1.06,−0.43; I2 = 67%, P < .00001), and lower level of neuron-specific enolase (SMD= −2.10; 95% CI: −2.85, −1.35; I2 = 85%, P < .00001). ERI plus SXN treatment provided significant improvements in whole blood high shear viscosity (SMD = −0.87; 95% CI: −1.17, −0.57; I2 = 0%, P < .00001), and whole blood low shear viscosity (SMD = −1.50; 95% CI: −1.65, −1.36; I2 = 0%, P < .00001) compared to ERI alone. Conclusion: ERI plus SXN showed better efficacy than ERI alone for patients with acute cerebral infarction. Our study provides evidence supporting the application of ERI plus SXN for acute cerebral infarction.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis

Zhou

Shanfen

2023

Medicine

View full text Add to dashboard Cite

show abstract

“…With the wide application of SXNI and the growing number of clinical studies, the number of systematic reviews (SRs) assessing its effectiveness and safety has also increased (Zhou et al, 2015;Wu et al, 2017;Fan et al, 2022). However, an umbrella review of these SRs has identified several shortcomings.…”

mentioning

confidence: 99%

Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis

Shi,

Sun,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) poses a serious threat to public health, and the current medical management still faces significant challenges. Reliable evidence on the efficacy of Shuxuening injection (SXNI) in CHD is still lacking, even though it is widely used in China.Purpose: To evaluate the efficacy of SXNI combination therapy in treating CHD.Methods: A systematic search of eight databases was conducted to identify relevant randomized controlled trials (RCTs) from the inception of each database until June 2023. ROB 2.0, RevMan 5.4, and Stata 15.1 were used for quality evaluation and data analysis. The Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the quality of evidence.Results: A total of 3,779 participants from 39 studies were included. The results showed SXNI combination therapy increased the clinical efficacy and decreased the frequency and duration of angina. Furthermore, SXNI combination therapy improved cardiac function of patients by decreasing LVEDD, and increased CI, CO, and LVEF. It also improved blood lipid profiles by increasing HDL, decreasing TC, TG, and LDL. The thrombosis factors of patients were also improved by decreasing FIB, PV, HCT, and HS. Moreover, SXNI combination therapy was superior to the conventional treatment in improving CRP levels, increasing ECG efficacy and BNP. However, due to the limited safety information, reliable safety conclusions could not be drawn. Furthermore, the levels of evidence ranged from very low to moderate due to publication bias and heterogeneity.Conclusion: SXNI can effectively improve angina symptoms, clinical efficacy, cardiac function, blood lipid indicators, and thrombosis factors of patients with CHD. However, more multi-center and large-sample studies are needed to confirm the conclusions due to the limitations of this study.Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=399606; Identifier: CRD42023433292.

show abstract

Effectiveness and safety of selected traditional Chinese medicine injections in patients with combined diabetes mellitus and coronary heart disease: A systematic review and network meta-analysis of randomized clinical trials

et al. 2023

View full text Add to dashboard Cite

Background: In view of the high morbidity and mortality of Diabetes mellitus—Coronary heart disease (DM-CHD) in diabetics, the combination therapy of traditional Chinese medicine injections (TCMIs) and conventional therapy (CT) is receiving extensive attention. Therefore, the effectiveness and security of conventional therapy with traditional Chinese medicine injections in the therapy of diabetes mellitus—coronary heart disease were compared by systematical review and network meta-analysis.Methods: According to the preset inclusion criteria and exclusion criteria, we searched seven electronic literature databases from their inception to JAN 5,2022, to obtain the relevant RCT literature on the therapy of diabetes mellitus—coronary heart disease with traditional Chinese medicine injections. Two researchers independently reviewed the papers, two other researchers worked in extracting data and quality assessment of the included literature. The primary outcomes were total effective rate. The secondary outcomes included electrocardiogram (EGG)effective rate, the effective rate of angina pectoris, fasting blood glucose (FBG), 2-h postprandial blood glucose (PBG), hemoglobinA1c (HbA1c), total cholesterol (TC) and triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), frequency of angina pectoris, and duration of angina pectoris. We adopted stata16.0 software for the systematic review and network meta-analysis.Results: A total of 53 trials involved 4,619 patients and one of the following 16 traditional Chinese medicine injections: Danhong, Danshen, Gualoupi, Gegen, Chuanxiongqin, Danshenchuanxiongqin, Shenmai, Shenqi, Xixin, Xuesaitong, Shuxuetong, Guanxinning, Kudiezi, Ciwujia, Xingding, Shuxuening. The meta-analysis revealed that Chuanxiongqin injection was superior to all other therapies in improving the total effective rate, [vs. conventional therapy odds ratio (OR): 14.52, 95% confidence interval (CI): 4.13–51.02], vs. Xuesaitong injection (odds ratio: 7.61, confidence interval: 1.25–46.40), and vs. Danshenchuanxiongqin injection (odds ratio: 3.98, confidence interval: 1.03–15.28)]. Xixin injection + conventional therapy was superior to conventional therapy only for electrocardiogram effective rate (odds ratio: 5.44, confidence interval: 1.55–19.18). Shenmai injection + conventional therapy was superior to conventional therapy in effective rate of angina (odds ratio: 11.05, confidence interval: 2.76–44.28). There was not different significantly in the comparisons of frequency of angina pectoris and duration of angina pectoris, we considered that this may be due to the lack of sufficient data. As most of the included RCTs did not monitor Adverse Events, the safety of those traditional Chinese medicine injections remains to be further explored.Conclusion: Basing on our study, traditional Chinese medicine injections combined with conventional therapy takes important role in the treatment of diabetes mellitus—coronary heart disease, and its curative effect is better than conventional therapy. Nevertheless, properly designed RCTs are required to validate our conclusions in the future.Systematic Review Registration: [https://inplasy.com/inplasy-2021-12-0125/], identifier [INPLASY2021120125].

show abstract

Systematic Review of the Efficacy and Safety of Shuxuening Injection in the Treatment of Unstable Angina

Cited by 3 publications

References 5 publications

Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis

Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis

Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis

Effectiveness and safety of selected traditional Chinese medicine injections in patients with combined diabetes mellitus and coronary heart disease: A systematic review and network meta-analysis of randomized clinical trials

Contact Info

Product

Resources

About